Kintor Pharmaceutical Limited (SEHK: 9939)
Health Care · Biotechnology · CN
HK$1.80
-2.71% today · -26.1% 1Y
Kintor Pharmaceutical Limited (SEHK: 9939) operates in the Biotechnology industry within the Health Care sector. The company is valued at $112.96M and employs 122 people.
Over the last twelve months the share price has lost 26.1%, trading between 1.60 and 4.70.
Tweenvest scores Kintor Pharmaceutical Limited across four factors: quality 23/100, value 74/100. Its strongest factor is value.
9939 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $112.96M
- Revenue (TTM)
- $11.59M
- P/E
- —
- EPS
- -0.40
- Dividend yield
- —
- Beta (5Y)
- -0.68
- 52-week high
- HK$4.70
- 52-week low
- HK$1.60
- Avg volume (3M)
- —
- Shares outstanding
- 493.81M
- Employees
- 122
- Next earnings
- —
About Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.
- ISIN
- KYG5273B1077
- Founded
- 2009
- Listed since
- May 22, 2020
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| 4basebio PLCAIM: 4BB | $115.64M | £5.63 | 0.00% |
| Genelux CorporationNasdaqCM: GNLX | $114.72M | $2.50 | -2.34% |
| Tenax Therapeutics, Inc.NasdaqCM: TENX | $113.42M | $1.86 | -6.06% |
| Hamlet BioPharma AB (publ)XSAT: HAMLET B | $113.40M | Skr6.08 | +1.50% |
| Coya Therapeutics, Inc.NasdaqCM: COYA | $112.83M | $4.99 | +3.74% |
| Inovio Pharmaceuticals, Inc.NasdaqCM: INO | $112.70M | $1.09 | -5.63% |
| Insight Molecular Diagnostics Inc.NasdaqCM: IMDX | $112.57M | $3.28 | -4.65% |
| Anterogen.Co.,Ltd.KOSDAQ: A065660 | $111.74M | ₩15,040.00 | +2.31% |
Figures last refreshed Oct 4, 2026.